ExploreWatchlistsPricing
  1. US-listed companies
  2. Adaptimmune Therapeutics PLC
  3. Financials
  4. Cash from investing

Adaptimmune Therapeutics PLC (ADAPY)

Market cap
$5.73M
P/E ratio
SummaryFinancials
Period EndCash from investing (Million USD)YoY (%)
Dec 31, 2024-59-133.39%
Dec 31, 2023177+98.05%
Dec 31, 202289+17.59%
Dec 31, 202176-127.18%
Dec 31, 2020-279-393.77%
Dec 31, 201995-643.88%
Dec 31, 2018-17-86.15%
Dec 31, 2017-126-810.12%
Dec 31, 201618

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat